Repurposing CD8+ T cell immunity against SARS-CoV-2 for cancer immunotherapy: a positive aspect of the COVID-19 pandemic?. (1st January 2020)

• Record Type: Journal Article
• Authors: Gujar, Shashi; Pol, Jonathan G.; Kim, Youra; Kroemer, Guido
• Is Part Of: Oncoimmunology. Volume 9:Number 1(2020)
• Publication Date: 2020-01-01
• Subjects: SARS-CoV-2 -- antiviral immunity -- cancer immunotherapy -- antigen spreading -- CD8+ T cell epitopes; Tumors -- Immunological aspects -- Periodicals; Neoplasms -- therapy -- Periodicals; Immunotherapy -- Periodicals; 616.994
• DOI: 10.1080/2162402X.2020.1794424
• Languages: English
• ISSNs: 2162-402X

Abstract

ABSTRACT: The COVID-19 pandemic has afflicted most countries on the planet. As a result, immunity against SARS-CoV-2, induced via natural infections or imminent vaccinations, is expected to develop in a large fraction of the global population. Here, we propose to exploit SARS-CoV-2-specific CD8 + T cells for cancer immunotherapy strategies.